masitinib + gemcitabine

Masitinib + gemcitabine is a combination therapy comprising **masitinib**, a selective oral tyrosine kinase inhibitor primarily targeting c-kit, platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), and **gemcitabine**, a nucleoside analog antimetabolite. This combination has been investigated primarily for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC), especially in patients with unresectable, locally advanced or metastatic disease. Clinical trials indicate that the combination may offer improved outcomes, particularly for subgroups defined by pain criteria or specific biomarkers (e.g., ACOX1 overexpression), with manageable toxicity. Masitinib is developed and manufactured by AB Science and is administered orally, while gemcitabine is given intravenously[1][3][5].